medigraphic.com

2006, Number 6

<< Back

Rev Med Inst Mex Seguro Soc 2006; 44 (6)

Non Steroidal Anti-inflammatory Analgesics in Pain Treatment. Orientation for Use them at First Level of Medical Attention

Vladislavovna DS, Torres ALP, Reyes MH

Language: Spanish
References: 50
Page: 565-572
PDF size: 187.01 Kb.


ABSTRACT

The high use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the current practice at the primary care level, and their frequently inappropriate prescription, due to ignorance in pharmacological side effects could cause devastating consequences for the patient’s health. It was considered necessary to make a review of the more recent evidence about the NSAIDs, with the intention that medical doctors can be updated on the use of these drugs. The literature review was performed at the Ovid-Medline, Cochrane, Synergy, Medic latina, Science direct, Ebsco-e-journal services. In this article there is an emphasis about NSAIDs adverse effects, and actions suggested during their use.


REFERENCES

  1. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:3:1000-1016.

  2. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272:781-786.

  3. Kendall BJ, Peura DA. NSAID-associated gastrointestinal damage and the elderly. Pract Gastroenterol 1993;17:13-29.

  4. Thomas E, Peat G, Harris L, Wilkie R, Croft PR. The prevalence of pain and pain interference in a general population of older adult cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). Pain 2004; 110:361-368.

  5. 5. Tamblyn R, Berkson L, Dauphinee WD, Gayton D, Grad R, Huang A, Isaac L, McLeod P, Snell L. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127: 429-438.

  6. 6. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother 2002;36:1238-1248.

  7. 7. Glazier RH, Dalby DM, Badley EM, Hawker GA, Bell MJ, Buchbinder R, Lineker SC. Management of common musculoskeletal problems: a survey of Ontario primary care physicians. CMAJ 1998; 158:1037-1040.

  8. 8. Anderson GM, Beers MH, Kerluke K. Auditing prescription practice using explicit criteria and computerized drug benefit claims data. J Eval Clin Pract 1997;3:283-294.

  9. 9. Keys J, Beardon PH, Lau C, Lang CC, McDevitt DG. General practitioners’ use of non-steroidal anti-inflammatory drugs in Tayside and Fife regions. J R Soc Med 1992;85:442-445.

  10. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preven-tability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-1116.

  11. Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, Meyer GS. Poten-tially inappropriate medication use in the com-munity-dwelling elderly. Findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001;286: 2823-2829.

  12. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in pres-cribing for elderly people: a national consensus panel. Can Med Assoc J 1997;156:385-391.

  13. Ruoff G. Management of pain in patients with multiple health problems: a guide for the practicing physician. Am J Med 1998;105:53-60.

  14. Conaway DC. Using NSAIDs safely in the elderly. Hosp Med May 1995:1-9.

  15. Rank AK. Los analgésicos antiinflamatorios no esteroideos. Dol Clin Ter 2002;2:5-10.

  16. 16 . Thomson MICROMEDEX. Drug Reference Guides. Drug Information for the Health Care Professional. Vol. 1. USP DI®; 2005.

  17. Garner S, Fidan D, Frankish R, Judd M, Shea B, Towheed T, Wells G, Tugwell P. Celecoxib for rheumatoid arthritis. The Cochrane Database of Systematic Reviews 2005;1. Disponible en http://www.cochrane.org

  18. Oxford league table of analgesics in acute pain. Copyright 1994-2005. Disponible en http://www. pubmedcentral.nih.gov/redirect.cgi?&&reftype =extlink&artid =534841&&www. jr2.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/Leagtab.html

  19. Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P. Rofecoxib for rheumatoid arthritis. The Cochrane Database of Systematic Reviews 2005;1. Disponible en: http://www.cochrane.org

  20. Walker JS. NSAID an update on their analgesic effects. Clin Exp Pharmacol Physol 1995;22:855-860.

  21. WHO Collaborating Centre for International Drug Monitoring. Viewpoint Part 1. Uppsala, Sweden: The Uppsala Monitoring Centre; 2003.

  22. Rodríguez-Betancourt L, García-Vigil JL, Giral- Barnés C, Hernández-Santillán D, Jasso-Gutiérrez L. Farmacovigilancia III. La experiencia interna-cional. Rev Med IMSS 2005;43(2):131-140.

  23. Yost JH, Morgan CJ. Cardiovascular effects of NSAIDs. J Musculoskel Med 1994;11:22-34.

  24. Johnson AG, Nguyen TV, Day RO. Do nons-teroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121:289-300.

  25. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997;17:277-289.

  26. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777-784.

  27. Conlin P, Moore T, Swartz S, Barr E, Gazdick L, Fletcher CH, DeLucca P, Demopoulos L. Effect of indometacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000;36:461-465.

  28. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-598.

  29. Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of nonsteroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case control study. Br J Clin Pharmacol 1997;44:85-90.

  30. Gambaro G, Perazella MA. Adverse renal effects on anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253:643-652.

  31. Sturmer T, Erb A, Keller F, Günter KP, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med 2001;111:521-527.

  32. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS. Miso-prostol reduces serious gastrointestinal compli-cations in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:4:241-249.

  33. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1998;41:1-16.

  34. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med 1996;101:25-32.

  35. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;28(Suppl):6-10.

  36. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311: 1206-1211.

  37. Singh G. Recent considerations in nonsteroidal anti-inflamatory drug gastropathy. Am J Med 1998;105:31-38.

  38. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal anti-inflammatory drug-induced side effects of the upper gastrointestinal tract. Arthr Rheum 1989; 32:926-932.

  39. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-1088.

  40. Lewis SC. Langman MJS, Laporte JR, Mattews ANS, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin non-steroidal anti-inflamatory drugs and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-326.

  41. García-Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-772.

  42. Lanza LL, Walker AM, Bortnichak EA, Dreyer NA. Peptic ulcer and gastrointestinal hemmorahage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med 1995;155:1371-1377.

  43. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, Bardhan KD. Emergency admis-sions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-291.

  44. Martindale. The complete drug reference. 34th edition. London, England: Pharmaceutical Press; 2004.

  45. Routledge P, Vale JA, Bateman DN, Johnston GD, Jones A, Judd A, Thomas S, Volans G, Prescott LF, Proudfoot A. Paracetamol (acetaminophen) poisoning. No need to change current guidelines to accident departments. BMJ 1998;317:1609-1610.

  46. The American Geriatrics Society. The manage-ment of persistent pain in older persons. AGS Panel on Persistent Pain in Older Persons. J Am Geriatr Soc 2002;50(Suppl):205-224.

  47. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PJ, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;9339:1071-1073.

  48. Gloth FM. Concerns with chronic analgesic therapy in elderly patients. Am J Med 1996;101: 19-24.

  49. Tollison JW. Special considerations in pharma-cologic pain management. Handbook of Pain Management. Second edition. Baltimore: Williams and Wilkins; 1994.

  50. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. The Cochrane Database of Systematic Reviews 2004;1. Dispo-nible en http://www.cochrane.org




2020     |     www.medigraphic.com